riluzole and Recrudescence

riluzole has been researched along with Recrudescence in 3 studies

Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.

Research

Studies (3)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Children's Yale-Brown Obsessive-Compulsive Scale Scores (CY-BOCS)

CY-BOCS is a 0-40 point scale of obsessive-compulsive symptom severity, higher number indicates more severe obsessive-compulsive symptoms. Comparison of 12 weeks scores for placebo and riluzole groups. (NCT00251303)
Timeframe: 12 weeks

Much/Very Much Improved on Clinical Global Impressions - Improvement Score (CGI-I)

(NCT00251303)
Timeframe: 12 weeks

Change in Montgomery and Asberg Depression Rating Scale (MADRS)

"This 10 item instrument is completed by the clinician by using a structured interview and defined anchor points, and aims to quantify the degree of depression over the past 7 days. The MADRS is a widely studied instrument for depression, and its reliability and validity are high. This instrument is administered at every study visit during the double-blind RCT, and at the screening, and baseline. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60.~Usual cutoff points are:~0 to 6 - normal/symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression" (NCT01204918)
Timeframe: 4 weeks of therapy (baseline to week 4)

Change in Montgomery and Asberg Depression Rating Scale (MADRS)

"This 10 item instrument is completed by the clinician by using a structured interview and defined anchor points, and aims to quantify the degree of depression over the past 7 days. The MADRS is a widely studied instrument for depression, and its reliability and validity are high. This instrument is administered at every study visit during the double-blind RCT, and at the screening, and baseline. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60.~Usual cutoff points are:~0 to 6 - normal/symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression" (NCT01204918)
Timeframe: 4 weeks of therapy (week 4 to week 8)

Responders Having at Least a 50% Improvement in MADRS Compared to the Baseline

Responders having at least a 50% improvement in MADRS compared to the baseline in the sequential parallel design (NCT01204918)
Timeframe: 8 weeks therapy

Systematic Assessment for Treatment Emergent Events (SAFTEE-SI)

A commonly used instrument originally developed by NIMH and adapted into a self-report instrument. The version of the scale that we plan to use examines in a systematic fashion all possible treatment-emergent side effects and probes specific adverse symptoms, including suicidal thoughts and behaviors, and self-injurious behavior. Presented below are counts of people that had experienced the event by 8 weeks. (NCT01204918)
Timeframe: 8 weeks

Mean Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to the End of 8 Weeks of Therapy.

The Montgomery Asberg Depression Rating Scale measures symptoms of depression (MADRS) is a semi-structured interview rating scale for depression that assesses 10 symptoms. The scale is composed of 10 questions with a fixed 7 point scale (0-6). Total score ranges from 0-60. A higher score indicates more depressive symptoms. MADRS Response will be defined as a > 50% reduction in MADRS score from baseline. (NCT00376220)
Timeframe: 8 weeks

Reviews

1 review available for riluzole and Recrudescence

Trials

1 trial available for riluzole and Recrudescence

Other Studies

1 other study available for riluzole and Recrudescence